Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded by StockNews.com to Buy

StockNews.com upgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a hold rating to a buy rating in a research report report published on Tuesday morning.

Separately, HC Wainwright reissued a “neutral” rating on shares of Oramed Pharmaceuticals in a research report on Monday, September 9th.

Oramed Pharmaceuticals Trading Up 1.1 %

Shares of NASDAQ ORMP opened at $2.37 on Tuesday. The stock has a fifty day moving average price of $2.39 and a 200 day moving average price of $2.39. Oramed Pharmaceuticals has a 12-month low of $1.67 and a 12-month high of $3.67. The company has a market cap of $96.62 million, a P/E ratio of 4.65 and a beta of 1.77.

Oramed Pharmaceuticals (NASDAQ:ORMP) last announced its earnings results on Wednesday, August 14th. The biotechnology company reported $0.22 EPS for the quarter, beating the consensus estimate of $0.01 by $0.21. On average, sell-side analysts forecast that Oramed Pharmaceuticals will post 0.24 EPS for the current fiscal year.

Institutional Trading of Oramed Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of ORMP. XTX Topco Ltd acquired a new stake in Oramed Pharmaceuticals during the 2nd quarter valued at approximately $40,000. Virtu Financial LLC bought a new stake in shares of Oramed Pharmaceuticals in the first quarter worth $68,000. Dimensional Fund Advisors LP raised its holdings in Oramed Pharmaceuticals by 52.1% in the second quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock valued at $81,000 after acquiring an additional 10,774 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Oramed Pharmaceuticals by 89.0% during the 2nd quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock valued at $593,000 after acquiring an additional 108,700 shares during the last quarter. Finally, Murchinson Ltd. boosted its stake in Oramed Pharmaceuticals by 31.4% during the 1st quarter. Murchinson Ltd. now owns 1,379,495 shares of the biotechnology company’s stock valued at $4,028,000 after acquiring an additional 329,495 shares during the last quarter. 12.73% of the stock is owned by hedge funds and other institutional investors.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.